OMass Therapeutics’ Post

Developing accurate animal models for ventilator-associated pneumonia faces numerous obstacles, including replicating the complex human lung environment and the precise conditions and stress induced by mechanical ventilation. In our recent paper, we describe the development of a novel and robust in vivo model for VAP, which successfully recapitulates a pulmonary environment during VAP . Our model accurately mimics the pathophysiological conditions seen in human patients with severe VAP, providing a valuable tool for studying the disease and testing potential treatments. This advancement is crucial for improving our understanding of VAP, adjusting PK/PD of new and approved antimicrobials, and ultimately enhancing patient outcomes. #VentilatorAssociatedPneumonia #VAP #MedicalResearch #CriticalCare #InfectiousDiseases #Pharmacology #PKPD #HealthcareInnovation #PatientOutcomes #MedicalScience #ResearchAndDevelopment https://lnkd.in/d-yrqgnw

Today is World Thrombosis Day, observed on 13th October to mark the birthday of Rudolf Virchow, a German pioneer of the pathophysiology of thrombosis. Thrombosis, commonly known as blood clots within vessels, contributes to 1 in 4 deaths worldwide and is a leading cause of cardiovascular death. This year’s theme urges everyone to Move Against Thrombosis, and raise awareness of risk factors, signs and symptoms. To learn more and support World Thrombosis Day, visit www.worldthrombosisday.org. Quadratech Diagnostics Ltd are committed to offering an extensive portfolio of diagnostic reagents for investigating coagulation pathways, haemophilia, thrombophilia, fibrinolysis and platelet function, alongside diagnostic tests for antithrombotic drug monitoring and thrombodynamics. To learn more, visit: https://lnkd.in/g9FsZhvr. #WTDay24 #worldthrombosisday #quadratechdiagnostics #ISTH #medicaldiagnostics #medicalsupplies #research

🌟 Exciting Research Discovery! 🌟 New study reveals lansoprazole, a widely-used proton pump inhibitor, may protect against liver injury caused by isoniazid, a common antitubercular drug. 🧬 Using innovative approaches including zebrafish models and patient health records, researchers at Mie University identified LPZ's potential in mitigating drug-induced liver injury. 🐟🔬 Stay tuned for more updates on this promising avenue for drug repositioning! #LiverHealth #DrugDiscovery #ScienceNews

Experts examine the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management. Watch this series to learn more about AD treatment options: https://bit.ly/4eEW7uS #ManagedCare #AtopicDermatitis

🚀 Hot from EASL 2024! 🚀 Today, Arun Sanyal presented groundbreaking data on Boehringer Ingelheim’s survodutide, showing a breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis. This news builds on our previously announced primary endpoint, where up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%). The new data on the secondary endpoint shows that up to 52.3% of adults with fibrosis stages F1, F2, and F3 had improvement in fibrosis due to MASH. Moreover, additional sub-analysis reveals that up to 64.5% of adults with F2 and F3 fibrosis (moderate to advanced scarring) achieved an improvement in fibrosis without worsening of MASH #LiverHealth #MedicalResearch #Biotechnology #BoehringerIngelheim #Survodutide #MASH

Limus-based drug-eluting devices, like the #SELUTIONSLR™ Drug Eluting Balloon, hold significant potential for improving outcomes in patients with PAD. These devices are designed to deliver anti-proliferative medications directly to the site of arterial blockage, inhibiting excessive cell growth and reducing the risk of restenosis (re-narrowing of the artery) after treatment. By utilizing innovative drug delivery technology, limus-based devices can effectively target the underlying causes of arterial blockage, promoting long-term patency and enhancing vascular function. This approach offers several potential benefits for patients, including reduced rates of repeat interventions, improved symptom management, and enhanced quality of life. Overall, the #LIMUSFLOW trial represents a critical step forward in advancing the field of interventional cardiology and providing new treatment options for patients with PAD. The findings from this trial have the potential to shape clinical practice and improve outcomes for individuals living with this debilitating condition. #Cordis #GMSPakistan

Last article out! We developed a plasmonic biosensor for highly specific detection of α-synuclein toxic oligomers in biofluids as a strategy for early diagnosis of #Parkinson in a nice collaboration wit the lab of Laura M. Lechuga.        Highlights : - Plasmonic biosensing for identification and quantification of oligomeric α-Synuclein. - Based on the use of a novel peptide (PSMα3) as bioreceptor for direct fast detection. - PSMα3 targets only toxic oligomer aggregated forms of α-Syn with high specificity. - Full assay development with high sensitivity (0.13 nM) in cerebrospinal fluid. - Promising strategy for early and specific diagnosis of Parkinson's disease. More info at @PPMC_UAB https://lnkd.in/ddbvTqKA

Background α-Synuclein (αS) aggregation is the main neurological hallmark of a group of neurodegenerative disorders, collectively referred to as synucleinopathies, of which Parkinson's disease (PD) is the most prevalent. αS oligomers are elevated in the cerebrospinal fluid (CSF) of PD patients, standing as a biomarker for disease diagnosis. However, methods for early PD detection are still lacking. We have recently identified the amphipathic 22-residue peptide PSMα3 as a high-affinity binder of αS toxic oligomers. PSMα3 displayed excellent selectivity and reproducibility, binding to αS toxic oligomers with affinities in the low nanomolar range and without detectable cross-reactivity with functional monomeric αS. Results In this work, we leveraged these PSMα3 unique properties to design a plasmonic-based biosensor for the direct detection of toxic oligomers under label-free conditions. Significance and novelty We describe the integration of the peptide in a lab-on-a-chip plasmonic platform suitable for point-of-care measurements of αS toxic oligomers in CSF samples in real-time and at an affordable cost, providing an innovative biosensor for PD early diagnosis in the clinic.

Proud to share acceptance of our study as Late Breaking poster in the EASL Congress 2024 to be held in Milan, Italy, 05 to 08 June 2024. Our drug showing triple anti fibrotic effects. Thanks for my research team Johnny Amer, Ahmad Salhab and Baker Saffouri. Luji-1 reduces fibrosis by blocking Neuroligin-4 and β-neurexin and overexpressing thyroid hormone receptor-b, suggesting Rezdiffra sensitization and synergism in combination

Our latest research from Dr. Rehan's group introduces a groundbreaking approach to treat ulcerative colitis (UC). We’ve developed site-specific thiolated mucoadhesive anionic nanoliposomes that address the limitations of conventional enema therapy. This innovative delivery system, loaded with Gallic Acid (GA), offers targeted adhesion to inflamed colon sites, promoting prolonged drug residence and superior therapeutic efficacy. Our studies show that GATh@APDL effectively mitigates colonic inflammation, downregulates proinflammatory expressions, and enhances mucosal healing. 🌟 These findings represent a significant step forward in UC treatment, offering new hope for patients by overcoming the challenges of traditional therapies. We're excited about the potential of GATh@APDL in revolutionizing the management of UC. 🔗 https://lnkd.in/dwf6tbtV. Kindly share this article First ones are always special ones Special thanks to my supervisor @Rehan Khan for consistent support and suggestions and congratulations to all co-authors Ajay Kumar (Affiliate) MRSC @Anas Ahmad #UlcerativeColitis #Nanotechnology #DrugDelivery #MucosalHealing #InnovativeResearch #TeamScience